Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.
Villanueva V, Bermejo P, Montoya J, Toledo M, Gómez-Ibáñez A, Garcés M, Vilella L, López-González FJ, Rodriguez-Osorio X, Campos D, Martínez P, Giner P, Zurita J, Rodríguez-Uranga J, Ojeda J, Mauri JA, Camacho JL, Ruiz-Giménez J, Poza JJ, Massot-Tarrús A, Galiano ML, Bonet M. Villanueva V, et al. Acta Neurol Scand. 2017 Sep;136(3):254-264. doi: 10.1111/ane.12720. Epub 2016 Dec 9. Acta Neurol Scand. 2017. PMID: 27935017
Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study.
Villanueva V, Girón JM, Martín J, Hernández-Pastor LJ, Lahuerta J, Doz M, Cuesta M, Lévy-Bachelot L; Investigadores del estudio ESPERA. Villanueva V, et al. Neurologia. 2013 May;28(4):195-204. doi: 10.1016/j.nrl.2012.04.012. Epub 2012 Jun 27. Neurologia. 2013. PMID: 22743210 Free article. English, Spanish.
Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
Villanueva V, Serratosa JM, Guillamón E, Garcés M, Giráldez BG, Toledo M, Salas-Puig J, López González FJ, Flores J, Rodríguez-Uranga J, Castillo A, Mauri JA, Camacho JL, López-Gomáriz E, Giner P, Torres N, Palau J, Molins A. Villanueva V, et al. Epilepsy Res. 2014 Sep;108(7):1243-52. doi: 10.1016/j.eplepsyres.2014.04.014. Epub 2014 May 14. Epilepsy Res. 2014. PMID: 24908564
Drug-resistant epilepsy: definition and treatment alternatives.
López González FJ, Rodríguez Osorio X, Gil-Nagel Rein A, Carreño Martínez M, Serratosa Fernández J, Villanueva Haba V, Donaire Pedraza AJ, Mercadé Cerdá JM. López González FJ, et al. Neurologia. 2015 Sep;30(7):439-46. doi: 10.1016/j.nrl.2014.04.012. Epub 2014 Jun 26. Neurologia. 2015. PMID: 24975343 Free article. English, Spanish.
Associated Inosine to interferon: results of a clinical trial in multiple sclerosis.
Muñoz García D, Midaglia L, Martinez Vilela J, Marín Sánchez M, López González FJ, Arias Gómez M, Dapena Bolaño D, Iglesias Castañón A, Alonso Alonso M, Romero López J. Muñoz García D, et al. Acta Neurol Scand. 2015 Jun;131(6):405-10. doi: 10.1111/ane.12333. Epub 2014 Oct 14. Acta Neurol Scand. 2015. PMID: 25313094 Clinical Trial.
Early add-on lacosamide in a real-life setting: results of the REALLY study.
Villanueva V, Garcés M, López-Gomáriz E, Serratosa JM, González-Giráldez B, Parra J, Rodríguez-Uranga J, Toledo M, López González FJ, Bermejo P, Giner P, Castillo A, Molins A, Campos D, Mauri JÁ, Muñoz R, Bonet M, Serrano-Castro P, del Villar A, Saiz-Díaz RA; REALLY Study Group. Villanueva V, et al. Clin Drug Investig. 2015 Feb;35(2):121-31. doi: 10.1007/s40261-014-0255-5. Clin Drug Investig. 2015. PMID: 25488477
[Clinical experience with lacosamide in Galicia: the GALACO study].
Rodriguez-Osorio X, Lopez-Gonzalez FJ, Pato-Pato A, Cebrian-Perez E, Marey-Lopez J, Corredera-Garcia E, Rubio-Nazabal E, Castro-Vilanova MD, Abella-Corral J, Rodriguez-Regal A, Amigo-Jorrin MC, Pego-Reigosa R; en representación del grupo de estudio GALACO. Rodriguez-Osorio X, et al. Rev Neurol. 2015 Dec 16;61(12):536-42. Rev Neurol. 2015. PMID: 26662871 Free article. Spanish.
82 results